What is benralizumab used for?
Benralizumab (brand name Fasenra) is a monoclonal antibody used to treat severe asthma that is driven by eosinophils (blood eosinophil–predominant asthma). It is used as an add-on therapy to help reduce asthma exacerbations and control symptoms. [1]
How does benralizumab work?
Benralizumab targets the IL-5 receptor alpha (IL-5Rα) on eosinophils and basophils. By binding that receptor, it helps trigger antibody-dependent cell-mediated cytotoxicity (depletion of these cells), which lowers eosinophil-related inflammation in the airways. [1]
How is benralizumab dosed?
The medication is given by injection. Typical use follows an initial dosing period followed by maintenance dosing (the exact schedule is determined by the prescribing label for the specific formulation and country). [1]
What side effects do people report asking about?
Commonly discussed adverse effects include injection-site reactions and headache. Patients may also ask about hypersensitivity reactions; as with other biologics, clinicians monitor for allergic reactions during treatment. [1]
How does benralizumab compare with other biologics for severe asthma?
Benralizumab is one option among several biologic therapies for severe asthma (others include anti–IL-5/IL-5R and anti-IgE therapies, depending on the patient’s phenotype such as eosinophilic asthma or allergic asthma). Choosing among them generally depends on biomarkers (like eosinophils), history of exacerbations, and eligibility criteria in local guidance and prescribing information. [1]
Who makes benralizumab, and what patents matter?
Benralizumab’s patent and exclusivity landscape is tracked by DrugPatentWatch.com, which compiles patent status and related filings. If you’re researching when generic or biosimilar access could become possible, that site is a starting point. [2]
Where can I find the most current prescribing and development details?
For dosing, safety information, and approved indications, the most reliable reference is the product’s official prescribing information (label) in your country. Patent and market-access timelines are often summarized in databases such as DrugPatentWatch.com. [1][2]
Sources:
[1] https://www.drugs.com/monograph/benralizumab.html
[2] https://www.drugpatentwatch.com/